➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Dow
Baxter
Merck
Johnson and Johnson
Mallinckrodt

Last Updated: September 21, 2020

DrugPatentWatch Database Preview

Patent: 9,932,641

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,932,641
Title:Fusion genes associated with progressive prostate cancer
Abstract: The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at greater risk of developing progressive disease, and methods of treating the subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of \"progressive prostate cancer\"), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that no patient studied survived five years without recurrence if their primary prostate cancer contained a TRMT11-GRIK2 or MTOR-TP53BP1 fusion gene. It is also based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity.
Inventor(s): Luo; Jianhua (Wexford, PA), Yu; Yangping (Wexford, PA), Nelson; Joel B. (Pittsburgh, PA), Michalopoulos; George Konstantine (Pittsburgh, PA), Tseng; Chien-Cheng (Pittsburgh, PA), Ding; Ying (San Diego, CA)
Assignee: University of Pittsburgh--Of the Commonwealth System of Higher Education (Pittsburgh, PA)
Application Number:15/199,056
Patent Claims:see list of patent claims

Details for Patent 9,932,641

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Dendreon Pharmaceuticals Llc PROVENGE sipuleucel-t INJECTION 125197 001 2010-04-29   Start Trial University of Pittsburgh--Of the Commonwealth System of Higher Education (Pittsburgh, PA) 2033-12-30 search
Dendreon Pharmaceuticals Llc PROVENGE sipuleucel-t INJECTION 125197 1 2010-04-29   Start Trial University of Pittsburgh--Of the Commonwealth System of Higher Education (Pittsburgh, PA) 2033-12-30 search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Moodys
Harvard Business School
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.